Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12145514 | 0.82 | BRAF (0.31) | KDM4EBRAFCYP2C19CYP1A2 | |
| SCHEMBL10165035 | 0.77 | ALDH1A1 (0.46) | KDM4ECYP2C19NOS3NOS1 | |
| SCHEMBL17345678 | 0.77 | NOS1 (0.37) | KDM4EBRAFCHRNB2CHRNA4NOS3 | |
| SCHEMBL12735936 | 0.75 | CHRNB2 (0.33) | KDM4ECHRNB2CHRNA4NOS3NOS1 | |
| SCHEMBL13947613 | 0.73 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL13436334 | 0.72 | CHRNB2 (0.32) | KCNH2KDM4ECHRNB2CHRNA4HTR1D | |
| SCHEMBL15604420 | 0.72 | KCNH2 (0.52) | KCNH2KDM4ECYP2C19CYP1A2HTR1D | |
| SCHEMBL17996188 | 0.70 | HDAC6 (0.35) | KDM4E | |
| SCHEMBL823824 | 0.70 | GABRA1 (0.46) | KDM4EHTR1DLMNA | |
| SCHEMBL13068652 | 0.66 | CHRNA7 (0.55) | CYP2C19CHRNB2CHRNA4HTR1DHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | KCNH2 4307/4885KDM4E 33/4885BRAF 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.